Your session is about to expire
← Back to Search
Mitochondrial Metabolism Inhibitor
CPI-613 + HD Cytarabine and Mitoxantrone for Acute Myeloid Leukemia
Phase 3
Waitlist Available
Led By Jorge Eduardo Cortes, MD
Research Sponsored by Rafael Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Summary
This trial is testing whether adding CPI-613 to standard chemotherapy can improve outcomes in older patients with relapsed or refractory acute myeloid leukemia.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Complete Remission (CR)
Secondary outcome measures
CR+CRh
Overall Survival (OS)
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: CPI-613 + HD Cytarabine and MitoxantroneExperimental Treatment1 Intervention
CPI-613 + High Dose Cytarabine and Mitoxantrone
CPI-613 at 2,000 mg/m2/day from day 1 to 5.
Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 2nd and 5th doses of Cytarabine.
Group II: Control (HAM) and control sub-groups (MEC and FLAG)Active Control3 Interventions
High Dose Cytarabine and Mitoxantrone
Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 3rd and 5th doses of Cytarabine.
Mitoxantrone, Etoposide and Cytarabine
Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6
Fludarabine, Cytarabine and Filgrastim
Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5
Find a Location
Who is running the clinical trial?
Rafael Pharmaceuticals Inc.Lead Sponsor
8 Previous Clinical Trials
596 Total Patients Enrolled
Cornerstone PharmaceuticalsLead Sponsor
14 Previous Clinical Trials
661 Total Patients Enrolled
Jorge Eduardo Cortes, MDPrincipal InvestigatorAugusta University
Share this study with friends
Copy Link
Messenger